Penn Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Penn Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-268,785	Closed	-$9.02M	–	216
2026 Q1	$9.02M	Sell	268,785 -6,997	-3%	-$274K	0.7%	73
2025 Q4	$12.8M	Buy	+275,782	New	+$15.1M	1.02%	54

Penn Capital Management's SLNO Position: Q2 2026 in Review

Penn Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 268,785 shares — an estimated $9.02M sold.

Penn Capital Management first reported a position in SLNO in Q4 2025 and held it in 2 quarters. The position peaked at $12.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Penn Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Penn Capital Management sold 268,785 Soleno Therapeutics shares in Q2 2026, an estimated $9.02M.
Penn Capital Management first reported a position in Soleno Therapeutics in Q4 2025 and held it in 2 quarters.
Penn Capital Management's Soleno Therapeutics position peaked at $12.8M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.